Targeted therapy drug helps women with aggressive breast cancer live longer

Drug combination should be first line of treatment, UCLA researchers say
Dennis Slamon
Senior author Dr. Dennis Slamon says "there is absolutely no reason to wait" to give women treatment that combines ribociclib with hormone therapy.